

Ajanta Pharma Announces the Launch of Omeprazole and Sodium Bicarbonate Powder for Oral Suspension

Bridgewater, NJ – (September 26, 2016) – Ajanta Pharma USA Inc., a wholly owned subsidiary of Ajanta Pharma Ltd, announces today the launch of Omeprazole and Sodium Bicarbonate Powder for Oral Suspension, a bioequivalent prescription generic version of Zegerid®¹ Powder for Oral Suspension (20mg/1680mg and 40mg/1680mg), into the US market.

Omeprazole and Sodium Bicarbonate Powder for Oral Suspension is part of an ever-growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 26 Abbreviated New Drug Applications (ANDAs) of which it has 14 final ANDA approvals; 2 tentative approvals; and 10 ANDAs under review with the United States Food & Drug Administration.

About Ajanta Pharma

Ajanta Pharma Limited is a fully-integrated pharmaceutical company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing, and marketing quality, pharmaceuticals across 30+ countries.

For the financial year ended March 31, 2016, Ajanta's consolidated revenue stood at \$261 million and net profit of \$61 million. For the last five years, Ajanta has posted healthy performance with its consolidated revenue growing at 26% CAGR and net profit at 51% CAGR.

For more details about Ajanta Pharma USA Inc., please visit us at www.ajantapharmausa.com.

¹ Zegerid® is a registered trademark of Santarus Inc.

For more information, please contact:

John Adams

john.adams@ajantapharma.com

908.252.1165